1. Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

   Bouwstra, R., van Meerten, T. & Bremer, E., 1-Jan-2019, In : Molecular and Cellular Oncology. 6, 3, 1600349.

   Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

2. Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements

   Kahle, X. U., Hovingh, M., Noordzij, W., Seitz, A., Diepstra, A., Visser, L., van den Berg, A., van Meerten, T., Huls, G., Boellaard, R., Kwee, T. C. & Nijland, M., 26-Apr-2019, In : European Radiology. 11 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

   van der Galien, H. T., Hoogendoorn, M., Kibbelaar, R. E., van Meerten, T. & van Rijn, R. S., Jan-2019, In : Annals of Oncology. 30, 1, p. 151-152 2 p.

   Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

4. CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

   Van Meerten, T., Bouwstra, R., He, Y., Janneke, D. B., Kooistra, H., Fehrmann, R., Ammatuna, E., Huls, G. & Bremer, E., 29-Nov-2018, In : Blood. 132, Suppl.1, 3 p.

   Research output: Contribution to journal › Meeting Abstract › Academic

5. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis

   He, Y., Bouwstra, R., Wiersma, V. R., de Jong, M., Lourens, H. J., Fehrmann, R., de Bruyn, M., Ammatuna, E., Huls, G., van Meerten, T. & Bremer, E., 1-Feb-2019, In : Nature Communications. 10, 1, 8 p., 533.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (14) »